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Tetrandrine identified in a small 
molecule screen to activate 
mesenchymal stem cells for 
enhanced immunomodulation
Zijiang Yang1,2,3,4,5, John Concannon6, Kelvin S. Ng1,2,3, Kathleen Seyb6, Luke J. Mortensen7, 
Sudhir Ranganath1,2,3,8, Fangqi Gu1,2,3, Oren Levy1,2,3, Zhixiang Tong1,2,3, Keir Martyn1,2,3, 
Weian Zhao9, Charles P. Lin2,4, Marcie A. Glicksman2,6 & Jeffrey M. Karp1,2,3
Pre-treatment or priming of mesenchymal stem cells (MSC) prior to transplantation can significantly 
augment the immunosuppressive effect of MSC-based therapies. In this study, we screened a library 
of 1402 FDA-approved bioactive compounds to prime MSC. We identified tetrandrine as a potential hit 
that activates the secretion of prostaglandin E2 (PGE2), a potent immunosuppressive agent, by MSC. 
Tetrandrine increased MSC PGE2 secretion through the NF-κB/COX-2 signaling pathway. When co-
cultured with mouse macrophages (RAW264.7), tetrandrine-primed MSC attenuated the level of TNF-α 
secreted by RAW264.7. Furthermore, systemic transplantation of primed MSC into a mouse ear skin 
inflammation model significantly reduced the level of TNF-α in the inflamed ear, compared to unprimed 
cells. Screening of small molecules to pre-condition cells prior to transplantation represents a promising 
strategy to boost the therapeutic potential of cell therapy.
Mesenchymal stem cells (MSC) represent a promising cell type for therapeutic immunomodulation and tissue 
regeneration. Transplanted MSC can exert their therapeutic effects through several pathways including differ-
entiation into mature cell types; mitochondrial transfer; secretion of regulatory and trophic factors (secretome) 
in response to biological stimuli; or through release of extracellular vesicles carrying mRNA or miRNA1–5. 
Importantly, MSC exhibit a robust immunomodulatory effect6–8. Although the underlying mechanisms have 
yet to be conclusively elucidated, MSC have been shown to modulate the function of cell populations includ-
ing T and B lymphocytes9–11, natural killer cells12,13, and antigen-presenting cells such as dendritic cells and 
macrophages7,14–16. While most studies suggest that MSC can function through an immunosuppressive/inhib-
itory role, others show that MSC can exhibit pro-inflammatory properties17,18. Due to the high heterogeneity 
of MSC between donors, tissue origins and culture methods, the profiles of secretome produced by MSC are 
highly variable. Thus, manipulation of MSC prior to transplantation is important to consider to maximize immu-
nomodulatory potency and control therapeutic outcomes. In an attempt to increase the immunomodulatory 
potency of MSC, several strategies have been examined. IFN-γ priming of MSC has been explored to enhance 
direct and indirect inhibitory modulation of T cell responses19 by inducing immunosuppressive factors such as 
indoleamine-2,3-dioxygenase (IDO), inducible nitric oxide synthase (iNOS), and prostaglandin E2 (PGE2). The 
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clinical efficacy of IFN-γ -primed MSC as compared to unprimed MSC was reviewed in detail by Sivanathan, 
et al.19. MSC genetically transfected with interleukin-10 (IL-10) mRNA showed a superior anti-inflammatory 
effect in vivo20. Bartosh, et al. reported that MSC spheroids formed in hanging drops express high amount of 
TNF-α stimulated gene/protein 6 (TSG-6), stanniocalcin-1, IL-24, TNF-α -related apoptosis inducing ligand, 
and CD8221. MSC engineered with budesonide-loaded PLGA microparticles have also been explored to enhance 
IDO activity22. In particular, small molecule pre-conditioning represents an attractive approach that is amenable 
to treatment of large numbers of cells for clinical scale production, yet to date, most studies modified MSC func-
tion by utilizing limited selection of well-established factors to manipulate classic immunoregulatory genes. In 
this study, we established a high-throughput screening (HTS) protocol to identify bioactive molecules that can 
specifically enhance secretion of a candidate immunomodulatory molecule, Prostaglandin E2 (PGE2) that has 
been implicated as a key component of the MSC secretome8,23–26.
Results
Development of high-throughput screen and selection of a positive control. To develop an assay 
to detect compounds that enhance PGE2 secretion of MSC, we implemented a strategy using primary human 
MSC from healthy donors. We titrated the cell number, examined the time course, and identified the best media 
for the screen. We found that incubating 1500 cells/well in 384-well format overnight and assaying 24 h later was 
best for cell metabolic activity and for measuring secreted PGE2 by Homogeneous Time-Resolved Fluorescence 
(HTRF) technology. Figure 1 illustrates the outline of the screen. TNF-α and IFN-γ were both reported to activate 
PGE2 secretion27–29. To select a suitable stimulus as a positive control, we treated MSC with 100 ng/mL TNF-α or 
100 ng/mL IFN-γ and assayed for PGE2 after 6, 12, and 24 h. TNF-α induced PGE2 secretion as early as 6 h and 
the amount of PGE2 appeared to increase linearly throughout the 24 h assay (Supp. Fig. 1A). Neither treatment 
affected cell proliferation or metabolic activity (Supp. Fig. 1B). Therefore we chose to treat MSC with 100 ng/mL 
TNF-α for 24 h as the positive control.
Comparison between serum-containing αMEM and STEMPRO® MSC SFM. MSC had a smaller, 
more spindle-shaped morphology in STEMPRO® MSC SFM than in serum-containing α MEM (Supp. Fig. 2A). 
PGE2 secretion induced by TNF-α was relatively low (< 20%) when MSC were cultured in serum-containing 
α MEM for 24 h, but increased to ~50% in STEMPRO® MSC SFM (Supp. Fig. 2B). We therefore chose to use 
STEMPRO® MSC SFM to culture MSC to maximize the sensitivity of detection.
Assessment of DMSO concentration. To establish the HTS protocol, we tested whether the addition of 
DMSO (as a standard solvent for our library compounds) would affect the stability of PGE2 in the supernatant, 
the metabolic activity of MSC, or the activation by TNF-α . A 24-hour incubation of 250 pg/mL recombinant 
PGE2 into media containing 0%, 0.5% or 2% DMSO did not reduce the ability of HTRF to quantify levels of PGE2 
(Supp. Fig. 3A), suggesting that DMSO affected neither detection nor stability of PGE2. Next, we tested the meta-
bolic activity of MSC in media containing 0.5% or 2% DMSO after a 24-hour incubation using the MTS assay and 
found no effect on the number of viable cells (Supp. Fig. 3B). The secretion of PGE2 by MSC induced by TNF-α 
was not affected by treatment with 0.5% DMSO, but decreased by more than 50% in 2% DMSO (Supp. Fig. 3C). 
Since the final concentration of DMSO in the compound library screen was less than 0.1%, we concluded that 
DMSO concentration used in the compound library screen would not interfere with the secretion or detection 
of PGE2.
High-throughput screening (HTS) of the compound library. HTS of 1402 FDA-approved drugs and 
known bioactives was performed on MSC cultured in STEMPRO® SFM at a density of 1500 cells/well. In defined 
conditions (Fig. 1), all compounds were screened in duplicate and at two compound concentrations, 1 μ M and 
Figure 1. A schematic outline of the HTS approach. Cells were seeded into a 384-well plate on Day 1, and 
compounds were added on Day 2. On Day 3, the supernatant from each well was collected. The cells were re-
incubated in fresh medium containing MTS reagent for 2 h to assess cell metabolic activity (purple path), while 
the collected supernatants were assayed for another 24 h (Day 4) for (red path) HTRF-based PGE2 detection.
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10 μ M. The final concentration of DMSO was 0.1%. Hits were identified based on three times the standard devi-
ation of the basal level of activity and the activation threshold was set at 20%. While none of the compounds at 
1 μ M induced significant secretion of PGE2 (data not shown), 5 compounds were identified as putative PGE2 
activators at a concentration of 10 μ M (Fig. 2A, gray and yellow boxes). Four of the five compounds were active 
in both replicates.
Hits validation and EC50. The 5 putative PGE2 activators were assayed again in a 5-point dose response 
titration in quadruplicate using both HTRF and ELISA. Compound LDN-0096652 (tetrandrine), LDN-0213163 
(paroxetine hydrochloride) and LDN-0097842 (protriptyline hydrochloride) were confirmed to be active in both 
assays (Fig. 3A showed ELISA results). Their structures are shown in Fig. 2B. To measure EC50 and cytotoxicity, 
compounds were serially diluted along a 12-point curve (0.1 μ M–25 μ M, Fig. 3B–D, red line). Cell metabolism 
index (relative to unprimed cells, 1.0 represents that compound-primed cells exhibited the same metabolic activ-
ity as unprimed cells) was measured by the MTS assay (Fig. 3B–D, blue line). All three compounds at lower 
concentrations showed 20–40% increased MSC metabolism over unprimed cells. Similar to the HTS result, 
tetrandrine at 5 μ M–10 μ M increased PGE2 activity by ~30–35% with minimum cell cytotoxicity. Compound 
paroxetine hydrochloride and protriptyline hydrochloride upregulated PGE2 secretion at 10 μ M, but the effective 
concentrations were associated with significant cell death. We therefore chose tetrandrine as our top hit.
Kinetics and mechanism of tetrandrine-induced PGE2 Secretion. We next determined the dura-
tion of tetrandrine-induced (at 5 and 10 μ M) upregulation of PGE2. Cells were treated for 24 h with tetrandrine, 
then tetrandrine was removed and PGE2 secretion was monitored for an additional 1 or 2 days. The activation 
level of PGE2 was similar after tetrandrine removal at 24 h (DAY1) (5 μ M: 60.4 ± 9.5%; 10 μ M: 80.3 ± 5.6%) and 
48 h later (5 μ M: 59.1 ± 9.5%; 10 μ M: 75.8 ± 8.5%). On DAY3 the level decreased to 23.1 ± 4.2% and 49.4 ± 7.9%, 
respectively (P < 0.05, Fig. 4A).
As PGE2 synthesis is known to be regulated by NF-κ B/COX-2 signaling8,27,29, we examined if tetrandrine 
activated the same pathway. Indeed, the upregulation of PGE2 can be entirely disrupted by the addition of 1 mM 
NF-κ B pathway inhibitor, ammonium pyrrolidine dithiocarbamate (APD); or 5 μ M COX-2 inhibitor, NS-398 
(Fig. 4B), without affecting cell metabolic activity (data not shown). Interestingly, immunofluorescence staining 
of NF-κ B revealed that tetrandrine-induced upregulation and translocation of NF-κ B from cytoplasm to the 
nucleus within 6 h (Fig. 4C), which was later than TNF-α -induced upregulation and translocation of NF-κ B that 
happened within 30 min (Supp. Fig. 4).
Immunosuppression by tetrandrine-primed MSC. Finally, we verified the immunosuppressive effect 
of tetrandrine-primed MSC both in vitro and in vivo. In MSC/RAW264.7 co-culture experiments (Fig. 5A), 
unprimed MSC decreased TNF-α secretion by LPS-activated RAW264.7 by ~25% (P < 0.05). Interestingly, 
both 5 μ M and 10 μ M tetrandrine-primed MSC could further attenuate the level of TNF-α (76.9 ± 3.7% and 
80.4 ± 4.0% of unprimed MSC + LPS group, P < 0.05). This enhancement was completely blocked by the addition 
of either APD (100.6 ± 2.8%, P < 0.05) or NS-398 (96.6 ± 2.7%, P < 0.05) during MSC priming, suggesting that 
PGE2 and potentially other factors regulated by NF-κ B/COX-2 signaling in MSC played a direct role in regulat-
ing macrophage secretion of TNF-α .
Figure 2. High-throughput screening with a library of known bioactive compounds identified 5 
possible hits. (A) A total of 1402 bioactive compounds were screened in duplicate plates (blue and red dots) 
at a concentration of 10 μ M. Following a 24-hour treatment, the activation level was presented as a ratio 
to unprimed cells. Five compounds were flagged as potential hits (gray and yellow boxes) and 3 were later 
validated (yellow boxes). (B) Chemical structures of these 3 compounds are shown on the right. Red dash line: 
positive activation threshold at 20%; blue solid line: approximate level of activation achieved by a 24-hour 
treatment with the positive control, 100 ng/mL TNF-α (31.5 ± 0.04%, mean + SD).
www.nature.com/scientificreports/
4Scientific RepoRts | 6:30263 | DOI: 10.1038/srep30263
The suppression of TNF-α by tetrandrine-primed MSC was also confirmed in a mouse ear skin inflamma-
tion model (Fig. 5B). In the control group that did not receive any cell treatment, inflamed ear tissue had high 
amounts of TNF-α . Eighteen hours after the injection of unprimed MSC, the level of TNF-α in the inflamed ear 
did not significantly decrease. However, treatment with tetrandrine-primed MSC induced a significant decrease 
in TNF-α levels to 52.7 ± 10.3% of that in the unprimed MSC group. This indicates that tetrandrine-primed 
MSC, with enhanced secretion of PGE2, can achieve a much stronger immunosuppressive effect in vivo than that 
of unprimed MSC. Of note since all ear samples were immediately homogenized after harvest to preserve the 
half-life of TNF-α , we were not able to perform further pathological analyses in this study.
Discussion
Using a HTS approach, we have discovered that tetrandrine can effectively upregulate PGE2 secretion of MSC at 
non-toxic concentrations of 5 μ M and 10 μ M. This response is regulated through NF-κ B/COX-2 signaling and 
leads to enhanced immunosuppression in vivo.
Compared to genetic engineering of cells to promote surface expression and secretome production, prim-
ing cells with small molecules or cytokines is a potentially simpler, more cost-effective and rapid-to-perform 
approach. This type of transient induction to maximize therapeutic effect more closely resembles the in situ acti-
vation by host inflammatory mediators at pathological sites than a genetic-level modification. Priming approaches 
can be non-selective and selective. Non-selective strategies such as hypoxia, serum deprivation, or treatment with 
pleiotropic cytokines such as LPS, TNF-α , IFN-γ , activate multiple signaling pathways which collectively increase 
expression of downstream trophic factors or receptors30–37. Selective priming approaches target a single pathway 
or a limited number of related pathways to achieve a desired secretome or surface expression38–41. In this study 
we developed a HTS platform to identify compounds that perturb signaling pathways to enhance MSC secretion 
of PGE2, a potent immunosuppressive factor that regulates macrophages, T cells and dendritic cells7,8,14,26. Out of 
1402 known and FDA-approved bioactive compounds, 3 compounds were validated by both HTRF and ELISA 
assays, namely tetrandrine, paroxetine hydrochloride, and protriptyline hydrochloride. Paroxetine hydrochloride 
and protriptyline hydrochloride displayed high cytotoxicity at active concentrations. Only tetrandrine can acti-
vate MSCs at 5 μ M and 10 μ M with minimum cytotoxicity observed.
The immunoregulatory activity of MSC is at least in part achieved via the secretion of a variety of immu-
nosuppressive factors, such as PGE2, IL-10, TGF-β , nitric oxide, TNF-α -induced protein 6 (TSG-6), and 
IDO6–8,11,12,27,29. In our earlier work, we transduced MSC with IL-10 and homing ligands to enhance targeting to 
Figure 3. Validation of PGE2 activators and 12-point titration for EC50. (A) Each of the 3 compounds was 
confirmed via ELISA to activate PGE2 secretion by MSC, the activation % is presented as a ratio to unprimed 
cells. (B–D) 12-point titration for EC50 determination (red). The number of viable cells after 24-hour treatment 
(presented as metabolism index relative to unprimed cells) was measured by MTS assay (blue). Tetrandrine 
(LDN-0096652) was the only compound that activated PGE2 secretion without reducing cell metabolic activity. 
Blue dash line: metabolism index of unprimed cells.
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Figure 4. Tetrandrine activates PGE2 secretion through NF-κB/COX-2 signaling. (A) 1 × 104 MSC were 
primed with tetrandrine for 24 h (DAY 1) and then rinsed and cultured in fresh medium for additional 48 h 
(DAY 2 and 3). On each day supernatants were collected for PGE2 quantification and fresh medium was added. 
After tetrandrine was removed, the activation of PGE2 secretion was sustained at the same level for up to 24 h 
(DAY 2) and slightly decreased on DAY 3. (B) Addition of NF-κ B inhibitor APD or COX-2 inhibitor NS-398 
together with tetrandrine for 24 h completely abolished PGE2 secretion without affecting the cell metabolic 
activity. (C) Tetrandrine and 100 ng/mL TNF-α induced nuclear translocation of NF-κ B (white arrows) at 6 h. 
T-MSC: tetrandrine-primed MSC; * P < 0.05.
Figure 5. Tetrandrine-primed MSC attenuated TNF-α secretion by macrophages (in vitro) and in a mouse 
ear skin inflammation model (in vivo). (A) RAW264.7 mouse macrophages were treated with 100 ng/mL LPS for 
24 h and then co-cultured with MSC primed with 5 μ M or 10 μ M tetrandrine for 24 h, with or without inhibitors. 
Mouse TNF-α in the conditioned medium was measured by ELISA. (B) 1 × 106 tetrandrine-primed MSC 
were retro-orbitally injected into a mouse ear skin LPS-inflammation model. 18 h after injection, primed MSC 
significantly decreased the TNF-α level in the inflamed ear (LPS ear) compared to unprimed MSC, as detected via 
ELISA of homogenized ear tissue. T-MSC: tetrandrine-primed MSC; (L): LPS-stimulated; * , * * , * * * , †P < 0.05.
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inflamed tissues, and observed reduced inflammation in a mouse ear inflammation model20. Several studies have 
postulated PGE2 as one of the primary soluble mediators of immunomodulatory function in MSC11,12,27–29. PGE2 
secreted by MSC can induce the conversion of macrophages from a pro-inflammatory (M1) to anti-inflammatory 
phenotype (M2)8,14. Inhibition of PGE2 also has been shown to significantly mitigate MSC-mediated immuno-
suppression on both dendritic cells and activated T cells7,26. A recent study showed that the immunomodulatory 
ability of hMSC gradually declines with consecutive passages due to the alteration of COX-2 and PGE2 levels42.
Tetrandrine (CAS No. 518-34-3) is a bis-benzyl-isoquinoline alkaloid originally isolated from a Chinese 
medicinal herb, Radix Stephanae tetrandrae. Tetrandrine has been used traditionally to treat congestive cir-
culatory disorders and has been reported to modulate pathways associated with Ca2+ regulation, affecting 
endothelium-dependent relaxation, apoptosis, angiogenesis, anti-oxidation, and anti-inflammation43. It has 
been shown to inhibit voltage-gated Ca2+ channels (IC50 = 10.1 μ M), type II maxi-Ca2+-activated K+ channels 
(IC50 = 0.21 μ M) of rat neurohypophysial terminals44, and Ca2+-activated chloride channel in cultured human 
umbilical vein endothelial cells (IC50 = 5.2 μ M)45. Other studies have utilized tetrandrine at non-cytotoxic con-
centrations ranging from 0.1 μ M to 5 μ M, depending on cell type46–48. In this study, we verified that tetrandrine 
concentrations below 10 μ M were non-toxic to MSC since cell mitochondrial/metabolic activity and morphology 
were not significantly affected. While this study focused on tetrandrine, its molecular structure can potentially 
serve as a reference for further screening and optimization of small molecules that activate PGE2 secretion.
The activation and translocation of NF-κ B is involved in regulating the transcriptional activation of specific 
target genes and the expression of several pro-inflammatory factors49,50. When activated, NF-κ B separates from its 
inhibitor Iκ B and translocates from the cytoplasm to the nucleus where it controls gene expression, particularly 
activating COX-2 which catalyzes PGE2 synthesis51. Tetrandrine has been reported to be associated with NF-κ B 
signaling. Dang et al. recently showed that tetrandrine at 0.1 μ M to 1 μ M can suppress the NF-κ B and ERK signal-
ing pathways in LPS-activated microglia47. Specifically, at 50 μ M, tetrandrine abolished binding of NF-κ B to DNA 
and inhibited TNF-α release from LPS-activated rat primary microglial cells48 and at 5 μ M, tetrandrine can down-
regulate binding of NF-κ B to DNA when used to prime T cells before activating the T cells with inflammatory 
stimuli46. In contrast to the reported inhibitory effect of tetrandrine on NF-κ B, our study suggests that with MSC, 
NF-κ B activation is associated with tetrandrine-induced upregulation of PGE2. This is evidenced by data show-
ing that (i) the NF-κ B inhibitor APD or the COX-2 inhibitor NS-398 blocked PGE2 secretion by MSC entirely, 
and (ii) NF-κ B translocation was significantly more pronounced when tetrandrine or TNF-α was added to MSC. 
Moreover, tetrandrine-induced NF-κ B translocation was observed only after 6 h of incubation, which is relatively 
slow since TNF-α triggered NF-κ B translocation within 30 min. Nevertheless, the activation could be sustained 
up to 48 h after tetrandrine was removed from culture. Our data suggest that despite the NF-κ B suppression 
effect on cell types such as microglial and T cells, tetrandrine can trigger the activation of the NF-κ B signaling in 
MSC. Finally, it is possible that immunomodulatory factors regulators other than PGE2 were upregulated through 
NF-κ B or other pathways during tetrandrine treatment and additional studies are required to examine this.
Three observations in this study should be noted. First, the magnitude of enhancement of PGE2 secretion 
from MSC depended on whether MSC were treated in a 384- or 96-well format. In 384-well-format (1500 cells/
well, 30 cells/μ L), the average activation level of PGE2 by tetrandrine was ~30%, while in 96-well-format with 
similar dose per cell (5000 cells/well, 25 cells/μ L) it reached over 60%. This trend was repeatedly observed in 
this study. Secondly, MSC cultured in STEMPRO® MSC SFM before activation exhibited much lower but more 
consistent expression (< 50 pg/mL per well with seeding density at 1500 cells/well, coefficient of variation < 5%) 
of PGE2 compared to cells cultured in serum-containing α MEM (~200 pg/mL per well per well with seeding den-
sity at 800 cells/well, data not shown). Similarly, another study reported lower PGE2 secretion when MSC were 
cultured in serum-free media compared to serum-containing media37. Thirdly, it is possible that incubation with 
tetrandrine at lower concentration, i.e. ≤ 7 μ M, may stimulate MSC metabolism as indicated in Fig. 3B. Therefore 
the activation of PGE2 by 5 μ M tetrandrine may be amplified by the increased metabolic activity. Meanwhile, 
we used MTS assay to measure the mitochondrial/metabolic activity, which might not reflect the true number of 
cells. The correlation between tetrandrine-induced cell metabolism and PGE2 activation, as well as the difference 
between PGE2/metabolic activity and PGE2/cell numbers require further investigation. Of note, tetrandrine treat-
ment for 24 h did not alter the expression of MSC surface markers including CD73, CD90, CD44, CD105, CD34, 
CD11b, CD45, CXCR4, CD166, CD162, CD106, CD104, CD102, CD54, CD49d, CD49a, CD29, CD15, CD11a.
Maggini J, et al. reported that PGE2 produced by un-primed MSC was able to inhibit the production of TNF- α 
by activated macrophage52. In this study, the immunosuppression effect by MSC was enhanced following tetrandrine 
activation. When co-cultured with LPS-stimulated RAW264.7 macrophages, tetrandrine-primed MSC significantly 
attenuated TNF-α secretion by the macrophages, compared to unprimed MSC. Similar to previous reports53, we did 
not detect altered expression of CD206 on RAW264.7 in response to PGE2 (data not shown). Furthermore, in an 
LPS-induced mouse ear skin inflammation model, only the group that received tetrandrine-primed MSC showed a 
decreased level of TNF-α in the inflamed ear. The infusion of unprimed MSC did not exhibit any effect. This is simi-
lar to previous reports where local expression of TNF-α , IL-1β and IL-10 remained unchanged after implantation of 
unprimed MSC54. Interestingly, we have observed a similar trend that was reported in a recent study. By injecting MSC 
primed with a small molecule that can enhance the homing ability, we can reduce the TNF-α level in inflamed ear to 
~50% of the level for unprimed MSC treatment and effectively decrease the inflamed ear thickness55. It has been sug-
gested that the immunosuppressive effect of PGE2 requires MSC-to-macrophage contact8. For instance, PGE2 secreted 
by MSC can signal adjacent macrophages through the EP4 receptors and convert them to an anti-inflammatory phe-
notype14. However, the window for such cell-cell contact is limited in vivo since MSC largely depend on a “hit-and-run” 
mechanism20,56. We have shown that retro-orbitally injected MSC begin to extravasate at the site of inflammation as 
early as 2 h and almost 50% of the MSC complete extravasation within 6 h57. In this study, enhanced PGE2 secre-
tion was sustained for 48 h after tetrandrine was removed from culture. We anticipate that in the initial 24–48 h fol-
lowing transplantation, tetrandrine-primed MSC, compared to unprimed MSC, can more efficiently suppress local 
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macrophages at sites of inflammation by transiently secreting much more PGE2. Moreover, Pelus LM and Hoggatt J. 
reported that PGE2 can indeed enhance hematopoietic stem cell (HSC) engraftment by enhancing stem cell homing, 
survival and self-renewal58,59. Short-term exposure of HSC to PGE2 increases CXCR4 receptor expression. Durand EM, 
et al. also reported that an in-vivo interaction between PGE2 and the Wnt signaling pathways controls HSC engraft-
ment60 Since 50% of the transplanted MSC engrafted within 6 h and the transient activation of PGE2 can last for 
more than 24 h post injection, it is reasonable to speculate that tetrandrine activation might also result in higher cell 
engraftment and contribute to enhanced immunosuppression. Future studies are required to unveil the underlying 
mechanism.
The enhancement of PGE2 secretion can effect a variety of other factors besides TNF-α . Indeed, cytokines like 
PGE2, IDO, IL-4, IL-10, and TGF-ß are immunoregulatory and their expression can be simultaneously upreg-
ulated during inflammation through interactive signal pathways61. It is known that PGE2 can upregulate IDO1 
expression in circulating DCs and induce immune tolerance62. Injection of PGE2 can enhance IL-10 and attenu-
ate TGF- ß1 expression in aged rats63. The interplay between PGE2/COX2 and TGF- ß has been revealed by other 
studies64,65. It will be of interest to understand whether over expression of PGE2 by MSC can modulate other 
anti-inflammatory factors secreted by DCs, T cells and macrophages such as IL-10 and IDO both in vitro and 
in vivo.
Our current work establishes a framework for subsequent, more sophisticated HTS assays such as multiplex-
ing readouts of several immunoregulatory factors including IL-6, TSG-6, NO, IDO, IL-1, and IL-10. It is impor-
tant to note that the HTS was performed on bone marrow derived MSC and whether the effect of tetrandrine 
is conserved across different sources of MSC (e.g. adipose vs. bone marrow derived) or across multiple MSC 
donors requires further investigation. Given that adipose derived MSC express different surface markers66 and 
have higher proliferative capacity67, MSC from adipose tissue may respond differently to tetradrine priming. Also, 
tetrandrine may additionally regulate immune properties of MSC other than PGE2 secretion. The exact signaling 
pathways underlying tetradrine/PGE2 activation, e.g. the classical or the alternative pathway to activate NF-κ B, 
as well as the molecular targets through which tetradrine mediates the immune properties of MSC remain to be 
investigated. Additionally, more functional data is required to support the hypothesis that a small molecule pre-
conditioning regimen can enhance the therapeutic effect.
The potential utility of a small molecule-based approach to enhance MSC immunosuppression could 
be far-reaching. For instance, in addition to a simple pre-conditioning regimen, we have previously demon-
strated a “particle-in-cell” platform that enables storage and controlled release of small molecules from MSCs 
for weeks22,68,69. This platform enables small molecules such as tetrandrine to continually stimulate transplanted 
cells for weeks as the particles degrade. Identified small molecules can also be immobilized within implantable 
cell-encapsulation devices or scaffolds to controllably stimulate transplanted cells. In conclusion, high-throughput 
screening of small molecules for targeted cell activation is a versatile strategy to identify candidates that specifi-
cally stimulate important cell biological pathways and to enhance the therapeutic potential of transplanted cells. 
This technology may also find utility in other immune disease models such as inflammatory bowel disease, colitis 
and sepsis70,71, where pathological changes could be mediated by small molecules such as PGE2.
Methods
Cell and culture conditions. All methods regarding human subjects were approved by the Harvard 
University Committee On the Use of Human Subjects. All experimental methods were carried out in accordance 
with the approved protocols. Bone-marrow derived primary human MSC from two healthy donors were obtained 
from the Texas A&M Health Science Center, Institute for Regenerative Medicine (Temple, TX). Informed con-
sent was obtained from all subjects. MSC at passage 3–5 were cultured in either serum-containing or serum-free 
medium. The serum-containing medium comprised α MEM (Life Technologies, Carlsbad, CA) supplemented 
with 10% FBS (Atlanta Biologicals, Lawrenceville, GA), 1% L-Glutamine (Life Technologies, Carlsbad, CA) 
and 1% Penicillin-Streptomycin (Life Technologies, Carlsbad, CA). The serum-free medium consisted of 
STEMPRO® MSC SFM (Life Technologies, Carlsbad, CA) supplemented with 1% Penicillin-Streptomycin and 
1% L-Glutamine. The mouse leukemic monocyte macrophage cell line RAW264.7 (ATCC, Manassas, VA) was 
used to verify the immunosuppressive effect of MSC14. RAW264.7 was cultured in α MEM supplemented with 
10% FBS, 1% L-Glutamine and 1% Penicillin-Streptomycin.
High-throughput screening (HTS) assay. MSC were treated in a 384-well plate with a library containing 
1402 known and FDA-approved bioactive compounds (Prestwick, France; MicroSource, CT, USA). Figure 1 illus-
trates the 4-day HTS workflow. On day 1, cells were seeded into 384-well plates at a density of 1500 cells/well using 
Thermofisher Multidrop Combi (Thermo Scientific, Waltham, MA) and incubated for 24 h. Compounds were 
then transferred to the cell plates on day 2 for a final compound concentration of 1 or 10 μ M in 0.1% DMSO via 
Beckman Coulter Biomek NX Automated Liquid Handling System (Beckman Coulter, Brea, CA) and incubated 
for 24 h. On day 3, 10 μ L of supernatant was transferred to a white 384-well low-volume microplate (Proxiplate, 
PerkinElmer, Waltham, MA). The level of secreted PGE2 was detected by using Homogeneous Time-Resolved 
Fluorescence (HTRF) technology, a combination of fluorescence resonance energy transfer technology (FRET) 
with time-resolved measurement (62P2APE, Cisbio, Bedford, MA). The number of viable cells (indicated by 
metabolic activity) after compound treatment was detected by performing formazan production-based MTS cell 
metabolic activity assay (CellTiter 96® AQueous One Solution Cell Proliferation Assay MTS, Promega, Madison, 
WI) for 2 h. On day 4, the HTRF assay plates were read via a PerkinElmer EnVision Multilabel Plate Reader 
(PerkinElmer, Waltham, MA). The percentage of activation was calculated using the following formula:
= −
∗
Activation% [1 [(FRET Ratio Value For Treated Sample Well)/
(FRET Ratio Average For Untreated Control Sample Wells)]] 100
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Validation of hits. Confirmation of the hits was performed in a 5-point dose response titration via both 
HTRF and ELISA (Prostaglandin E2 Parameter Assay Kit, R&D Systems, Minneapolis, MN) assays. Validated hits 
demonstrated activity from two different assay formats and reagents thereby reducing the chance that they were 
selected based on artifacts of detection. The EC50 of compounds was determined from a 12-point dose response 
titration via HTRF assay.
Signaling pathway identification. MSC were seeded at 1 × 104 cells/well in 96-well plates. One day later 
cells were treated with 5 μ M or 10 μ M tetrandrine, with or without 1 mM ammonium pyrrolidine dithiocar-
bamate (APD) (Sigma-Aldrich, St. Louis, MO) or 5 μ M NS-398 (Cayman Chemical, Ann Arbor, MI), which 
selectively inhibit NF-κ B and COX-2 respectively. After 24 h, supernatants were collected and assayed for PGE2 
via HTRF assay. In another set of experiments, MSC were seeded in 24-well plates at a density of 3 × 104 cells/
well for 24 h and treated with 5 μ M or 10 μ M tetrandrine for 30 min or 6 h. Cells were then fixed with 4% para-
formaldehyde, permeabilized with 0.1% Triton-X, and incubated with rabbit anti-human NF-κ B/p65 antibody 
(622602, Biolegend, San Diego, CA) and FITC-conjugated goat anti-rabbit antibody (F9887, Sigma-Aldrich, St. 
Louis, MO). Nuclear translocation of NF-κ B was visualized using an epifluorescence microscope (Nikon Eclipse 
TE2000-U, Japan).
Kinetics of tetrandrine-induced upregulation of PGE2. MSC were seeded at 5000 cells/well in 96-well 
plates for 24 h and then treated with 5 μ M or 10 μ M tetrandrine. Following an additional 24 h, supernatants (Day 1) 
were collected and replaced with fresh medium every 24 h until Day 3. The amount of PGE2 secreted every 24 h 
was detected via HTRF assay.
Immunosuppressive effect of tetrandrine-primed MSC in vitro. RAW264.7 cells were seeded 
at 2 × 104 cells/well in 96-well plates for 24 h and activated with 100 ng/mL lipopolysaccharides (LPS) from 
Salmonella enterica serotype typhimurium (Sigma-Aldrich, St. Louis, MO) for an additional 24 h. MSC unprimed 
or primed with 5 μ M or 10 μ M tetrandrine for 24 h were seeded at 1 × 104 cells/well directly on top of RAW264.7 
cells. Supernatants were collected 24 h later. Mouse TNF-α in the supernatants was quantified using ELISA 
(Biolegend, San Diego, CA).
Animal study. All animal experimental protocols were reviewed and approved by the MGH Subcommittee 
on Research Animal Care. All experimental methods were carried out in accordance with the approved protocols. 
We used a mouse ear skin inflammation model to test the in vivo therapeutic effect of tetrandrine-primed MSC. 
Ten C57BL/6 mice were anesthetized by intramuscular injection of a combination of anesthetics (80 mg/kg ket-
amine and 12 mg/kg xylazine). Lipopolysaccharide (LPS) (30 μ g in 30 μ L saline) was injected intradermally into 
the dorsal side of the left ear using an insulin syringe. The right ear was injected with 30 μ L saline as an internal 
control. After 24 h, animals were divided into three groups: control group (n = 3) received no cell treatment; 
unprimed MSC group (n = 3) received 1 × 106 unprimed cells; tetrandrine-primed MSC (T-MSC) group (n = 4) 
received 1 × 106 cells primed with 5 μ M tetrandrine. All cells were injected retro-orbitally. At 18 h after injec-
tion, mice were sacrificed and both ears were harvested. The tissue samples were then homogenized in ice-cold 
extraction buffer (RIPA with 0.5% Tween-20) and homogenates were transferred to 1.5-mL microcentrifuge tubes 
followed by centrifugation at 13,000 × g for 10 min at 4 °C. The supernatants were stored at − 80 °C until analysis. 
The levels of mouse TNF-α in the samples were quantified using an anti-mouse TNF-α ELISA kit (Biolegend, 
San Diego, CA).
Statistical analysis. Unless otherwise stated, experiments were performed at least in triplicate, and data are 
presented as mean ± standard error of the mean. Unpaired Student’s t-test and one-way ANOVA with Scheffe’s 
test for posthoc comparison were used to compare group means, after testing for normality and equal variance 
of the data.
All statistical analyses were carried out in Graphpad Prism® . Statistical significance was inferred at a 2-sided 
p ≤ 0.05.
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